Lynk Pharmaceuticals Collaborates with Formation Bio on Innovative CNS Drug Development Lynk Pharmaceuticals partners with Formation Bio to advance LNK01006, a selective TYK2 inhibitor, into clinical testing and development.

Lynk Pharmaceuticals Collaborates with Formation Bio on Innovative CNS Drug Development #USA #Boston #Formation_Bio #Lynk_Pharmaceuticals #LNK01006

Formation Bio Acquires Rights to Groundbreaking CNS Penetrant TYK2 Inhibitor LNK01006 Formation Bio has secured global rights to LNK01006, a promising CNS-penetrant TYK2 inhibitor from Lynk Pharmaceuticals, enhancing their immunology portfolio.

Formation Bio Acquires Rights to Groundbreaking CNS Penetrant TYK2 Inhibitor LNK01006 #USA #New_York #Formation_Bio #Lynk_Pharmaceuticals #LNK01006

Lynk Pharmaceuticals Achieves FDA Approval for Innovative TYK2 Inhibitor LNK01006 Targeting Neurological Diseases Lynk Pharmaceuticals announces FDA IND approval for LNK01006, a novel allosteric TYK2 inhibitor, opening doors to new therapies for neuroinflammatory diseases.

Lynk Pharmaceuticals Achieves FDA Approval for Innovative TYK2 Inhibitor LNK01006 Targeting Neurological Diseases #USA #Boston #Lynk_Pharmaceuticals #LNK01006 #TYK2_Inhibitor